Anke Baum

Zongertinib in HER2-altered colorectal cancer: A pooled analysis of colorectal cancer patients from two clinical trials.

Dirk Arnold, Noboru Yamamoto, Frans Opdam, Kiyotaka Yoh et autres

3538 Background: Zongertinib, an irreversible TKI, selectively inhibits HER2 while sparing wild-type EGFR, thereby minimizing associated toxicities. Here, we present a pooled analysis of a subgroup of patients (pts) with HER2-positive colorectal cancer (CRC) who received zongertinib monotherapy in Phase Ia of …

de, jp, nl, ca, it, au, es, us, gb, at (code pays fourni par la source)

Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.

Izuma Nakayama, Bernard Gaston Doger de Spéville, David Berz, Silvia Foti et autres

3106 Background: Zongertinib, an irreversible TKI, selectively inhibits HER2 while sparing wild-type EGFR, thereby minimizing associated toxicities. Beamion BCGC-1 (NCT06324357) is an ongoing Phase Ib/II multicohort trial investigating zongertinib, as monotherapy or combined with other agents, in HER2-positive metastatic breast cancer, metastatic …

jp, es, us, it, cn, de, at (code pays fourni par la source)

Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): First results from a phase Ib/II trial.

Shigehisa Kitano, Matteo Simonelli, Ramón Yarza, Junhua Zhang et autres

1044 Background: Zongertinib, an irreversible TKI, selectively inhibits HER2 while sparing wild-type EGFR, thereby minimizing associated toxicities. Beamion BCGC-1 (NCT06324357) is an ongoing Ph Ib/II multicohort trial investigating zongertinib as monotherapy or in combination with other agents in HER2-positive mBC, metastatic colorectal …

jp, it, cn, us, de, at (code pays fourni par la source)

Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models

Ksenija Slavic Obradovic, Florian Ebner, Artem V. Artemov, Martina Miotto et autres

Second mitochondrial activator of caspase (SMAC) mimetics (SMACm) and bromodomain and extra-terminal domain (BET) inhibitors (BETi) are two distinct classes of novel anticancer therapeutics. So far, broad clinical benefit for either monotherapy has not been achieved, calling for effective combination strategies. We …

at, it, us (code pays fourni par la source)

491P Zongertinib in HER2-altered gastrointestinal cancers: Preclinical activity and clinical findings from a phase Ia study

Kiyotaka Yoh, M. Barve, D. Berz, Frans L. Opdam et autres

jp, gb, us, nl, de, cn, at, fr (code pays fourni par la source)

Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study.

David Berz, Frans L. Opdam, Daniela Maier, Kerstin Moeldner et autres

1023 Background: Preclinical studies have demonstrated that zongertinib, an irreversible TKI, selectively and potently inhibits oncogenic HER2 in a variety of cancer models. An ongoing Phase (Ph) Ia/Ib dose escalation/expansion trial (NCT04886804) has demonstrated preliminary clinical activity of zongertinib across a range …

us, nl, de, at, jp (code pays fourni par la source)

Supplementary Data Table 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

PRISM screen raw data.

Data from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

Abstract Mutations in ERBB2 (encoding HER2) occur in 2% to 4% of non–small cell lung cancer (NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for treating other HER2-dependent cancers, are ineffective in HER2-mutant NSCLC due to dose-limiting toxicities or suboptimal …

Supplementary Figure 5 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

High-throughput zongertinib PRISM drug sensitivity screen and biomarker analysis.

Supplementary Figure 4 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

High-throughput PRISM drug sensitivity screen in cancer cell lines.

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

Tempus data analysis results.

Supplementary Figure 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski et autres

In vitro biomarker modulation of (phospho-)protein and mRNA levels post poziotinib or zongertinib treatment.